Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 28, 2018

View Archived Issues

Keeping leptin active

Hif-1 during high oxygen promotes tumor cell resistance

Discovery of a novel, orally available, transient receptor potential channel 6 inhibitor

Galecto Biotech compound is an orally available drug for fibrosis and cancer

Merck & Co. reports development of a full allosteric agonist of GPR40

BAY-1753011 provides vascular protection and decongestion without RAAS stimulation

Mutabilis SAS synthesizes prodrugs of beta-lactamase inhibitors

Shire Human Genetic Therapies patents TGF-beta inhibitors

Aryl hydrocarbon receptor antagonists discovered at Phenex Pharmaceuticals

FDA approves Imbruvica with rituximab for Waldenstrom's macroglobulinemia

Bristol-Myers Squibb presents novel Nav1.7 inhibitor for the treatment of pain

Sienna releases first-in-human study data on SNA-125 in psoriasis

Parasite protein protects mice from hemorrhagic cystitis by inducing IL-4 expression

Grant supports further investigation of NVP-015 for genetic mitochondrial diseases

FDA approves Xerava to treat complicated intra-abdominal infections

European Commission approves Mepsevii for non-neurological manifestations of MPS VII

LEO Pharma discovers novel JAK1 inhibitor with high clearance and low bioavailability

Sirtuin 6 is behind epigenetic melanoma drug resistance

FDA issues complete response letter for Waylivra NDA

Genfit completes enrollment in phase IIa trial of elafibranor for primary biliary cholangitis

Poxel completes enrollment in Japanese TIMES 3 trial of imeglimin in type 2 diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...